about
Telephone delivered interventions for reducing morbidity and mortality in people with HIV infectionTelephone delivered interventions for reducing morbidity and mortality in people with HIV infectionAnti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation.Comparative Effectiveness and Toxicity of Statins Among HIV-Infected PatientsAbyssomicin 2 reactivates latent HIV-1 by a PKC- and HDAC-independent mechanism.HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.Aerobic fitness levels and validation of a non exercise VO2max prediction equation for HIV-infected patients on HAART.Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era.The challenge of finding a cure for HIV infection.Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells.Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy.Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts.Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States.Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice.
P2860
Q24202803-0879C9BA-3541-41F5-BEF4-86B53B81B241Q24234249-23A90AB8-240B-4AF3-A573-F32455B5A87EQ33798442-AEDE3F05-C481-483C-B274-9A68E1ABD3F0Q34146122-973BC21D-EC46-455C-BA21-F124FD3000AFQ35019859-528F00A0-E83A-42F5-89EB-E1A82E7E41CBQ35538357-7CEBDA85-DB11-43D7-B245-F48ACA4482E2Q35941280-8B2024B9-ABE3-4573-BA4E-F1871521008BQ36061343-0883A66B-9E9E-46F6-A582-B7AA27E2522AQ37315190-668F519E-6271-4F4C-9F31-3012FB406E84Q37407598-50A9665A-86F8-4E48-A5AB-2719B0D3C8C3Q37455285-69C56077-C6B7-476C-BB09-F0A942644036Q37505250-3413A2B1-9311-4EA0-9A92-1ADE5D0E38ABQ37665526-C6A8FE88-7682-4487-B5B0-331A4112A64FQ39041099-3D9F9FF0-9587-46F5-8FFD-2A61ECD93042Q50054188-64080E58-C467-4D6D-9A0C-2D1558B62E48
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cardiovascular risks of antiretroviral therapies.
@ast
Cardiovascular risks of antiretroviral therapies.
@en
type
label
Cardiovascular risks of antiretroviral therapies.
@ast
Cardiovascular risks of antiretroviral therapies.
@en
prefLabel
Cardiovascular risks of antiretroviral therapies.
@ast
Cardiovascular risks of antiretroviral therapies.
@en
P1476
Cardiovascular risks of antiretroviral therapies.
@en
P2093
Kristin Mondy
P304
P356
10.1146/ANNUREV.MED.58.072905.180040
P50
P577
2007-01-01T00:00:00Z